Oligomeric Abeta assay, joint reMYND-Amorfix offering
reMYND has partnered up with Amorfix Life Sciences Ltd. to offer a quantitative and sensitive measurement of Abeta aggregates for Alzheimer’s disease research to its clients
The Amorfix Aggregated Abeta Assay (A4 assay) detects the presence of aggregated Abeta in animal models of Alzheimer’s disease (AD) several months before conventional microscopic procedures, and hence can accelerate the preclinical screening of new treatments for AD. The detection of aggregated Abeta in pre-plaque brains of reMYND’s APP and APPxPS1 models, and thus coinciding with the early-onset cognitive impairment, is especially intriguing in the light of findings that soluble Abeta oligomers are significantly elevated in the brain of AD patients and correlate with cognitive decline.
Fill in the form and download a technology presentation to learn more about:
- The two steps involved in the quantitative and sensitive A4 assay
- The validation of the A4 assay using transgenic APP mouse brains
- How the A4 assay compares to classical IHC plaque detection
For all inquiries please contact Dr. An Tanghe at cro@remynd.com.
To learn more about the partnership between reMYND and Amorfix Life Sciences Ltd. for offering the A4-assay to reMYND’s CRO clients, read the joint Amorfix-reMYND press release.
Related to
More information
Fill in the form and download a concise overview of the aggregated Abeta assay.
